References of "Beckers, Albert"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailMedical Treatment in Cushing’s Syndrome : Dopamine Agonists and Cabergoline
Petrossians, Patrick ULg; Thonnard, Anne-Sophie ULg; Beckers, Albert ULg

in Neuroendocrinology (2010), 92((supp. 1)), 116-19

Dopamine (DA) is a catecholamine with a wide range of functions and whose five subtype receptors are found in different organs where they exert a mainly inhibitory action. Since this action may also ... [more ▼]

Dopamine (DA) is a catecholamine with a wide range of functions and whose five subtype receptors are found in different organs where they exert a mainly inhibitory action. Since this action may also appear in a number of secretory tumors in various locations, DA agonists have elicited some interest as a medical treatment for hypercorticism. Non-iatrogenic Cushing’s syndromes are due in 70% of the cases to a pituitary adrenocorticotropic hormone (ACTH) producing adenoma, and, less frequently, to an adrenal adenoma or an ectopic ACTH secretion by a neuroendocrine tumor. First-line treatment in Cushing’s syndrome consists of the surgical removal of the secreting tumor. However, surgery may not achieve a complete cure in a number of cases, hence emphasizing the potential benefit of a medical complementary treatment, which could also benefit patients as an alternative approach, either when waiting for, or when the patient is not eligible for surgery. Studies of corticotropic adenomas have shown that 80% of these tumors express D2 receptors. Clinical trials of DA agonists in Cushing’s disease have shown an inhibitory effect of these drugs with an inhibition of ACTH secretion and/or a decrease of tumor size. There are only a few cases of documented use of DA agonists in ectopic ACTH secretion, but when the tumor expresses DA receptors, DA agonists may represent a useful complementary treatment. DA receptors are also expressed in normal and tumoral adrenals, suggesting a potential use of DA agonists in Cushing’s syndrome secondary to adrenal tumors. However, clinical data regarding this specific situation are very scarce, maybe due to the relatively high rate of surgical cure of adrenal adenomas. In conclusion, DA agonists represent a potential preparatory or complementary treatment for endogenous Cushing’s syndrome, especially in Cushing’s disease. These compounds may be underused as suggested by the scarce number of publication and case reports in the literature. In the future, association of these drugs with somatostatin analogs may also prove beneficial. [less ▲]

Detailed reference viewed: 35 (6 ULg)
See detailHigh Kisspeptine-10 levels in obese hypogonadic patients : is kisspeptine-10 a periheral signal between metabolism and reproduction
Valdes Socin, Hernan Gonzalo ULg; Cavalier, Etienne ULg; Beckaert, A. C. et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 34 (8 ULg)
Full Text
See detailEtude génétique et anatomopathologique du syndrome de McCune-Albright chez l'adulte
Beckers, Albert ULg; Burlacu, M.; Thiry, Albert ULg et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 15 (7 ULg)
Full Text
Peer Reviewed
See detailThe Ratio of Parathyroid Hormone as Measured by Third- and Second-Generation Assays as a Marker for Parathyroid Carcinoma.
Cavalier, Etienne ULg; Daly, Adrian ULg; Betea, Daniela ULg et al

in Journal of Clinical Endocrinology and Metabolism (2010), 95

Background: Parathyroid carcinoma (PCa) is a rare disease that can be difficult to differentiate initially from severe benign parathyroid adenoma. PCa oversecrete the amino form of PTH, which is ... [more ▼]

Background: Parathyroid carcinoma (PCa) is a rare disease that can be difficult to differentiate initially from severe benign parathyroid adenoma. PCa oversecrete the amino form of PTH, which is recognized by third-generation but not by second-generation PTH immunoassays. In normal individuals, the third-generation to second-generation PTH ratio should be less than 1. Objective: Our objective was to study the utility of the third-generation to second-generation PTH ratio as a means of distinguishing PCa patients (n = 24) from control groups with and without disorders of calcium secretion, including patients on renal hemodialysis (n = 74), postrenal transplantation (n = 60), and primary hyperparathyroidism (PHP; n = 30). Setting and Design: We conducted a retrospective, laboratory-based study at tertiary referral academic centers. Results: The mean third-generation to second-generation ratio was 0.58 ± 0.10 in the dialysis patients, 0.54 ± 0.10 in the renal transplant group, 0.54 ± 0.12 in the elderly healthy patients, and 0.68 ± 0.11 in the PHP group. All 245 of these patients presented a PTH third-generation to second-generation ratio of less than 1. In contrast, we observed an inverted third-generation to second-generation PTH ratio of more than one in 20 PCa patients, whereas only four PCa patients had a normal ratio of less than 1. Conclusions: An inverted third-generation to second-generation PTH ratio occurred in the majority of patients with advanced PCa and was absent in all 245 relevant controls. A third-generation to second-generation PTH ratio higher than 1 had a sensitivity of 83.3% and a specificity of 100% among PHP patients as a marker for PCa. This ratio may be useful to identify patients with PCa earlier and to detect patients either at risk of developing PCa or those in whom recurrence is taking place. [less ▲]

Detailed reference viewed: 57 (9 ULg)
Full Text
Peer Reviewed
See detailManagement of acromegaly
Vasilev, Vladimir ULg; Daly, Adrian ULg; Zacharieva, Sabina et al

in F1000 Medecine Reports (2010), 2(54),

Acromegaly is caused by hypersecretion of growth hormone and resultant overproduction of insulinlike growth factor-1 and is associated with increased mortality and morbidity. Successful treatment ... [more ▼]

Acromegaly is caused by hypersecretion of growth hormone and resultant overproduction of insulinlike growth factor-1 and is associated with increased mortality and morbidity. Successful treatment modalities have been developed and are used in a multistep approach allowing normal life expectancy as well as improved quality of life in an increasing number of patients. [less ▲]

Detailed reference viewed: 22 (6 ULg)
See detailNouvelles perspectives dans l'exploration des déficiences hypophysaires
Beckers, Albert ULg; Valdes Socin, Hernan Gonzalo ULg

Scientific conference (2010, June 29)

Detailed reference viewed: 8 (1 ULg)
See detailLe tabac et ses effets sur le système endocrinien
Beckers, Albert ULg

Scientific conference (2010, June 09)

Detailed reference viewed: 43 (2 ULg)
Full Text
Peer Reviewed
See detailThe genetics of pituitary adenomas
Vandeva-Kalvacheva, Silvia ULg; Jaffrain-Rea, M. L.; Daly, Adrian ULg et al

in Best Practice & Research. Clinical Endocrinology & Metabolism (2010), 24(3), 461-76

Pituitary adenomas are one of the most frequent intracranial tumors with a prevalence of clinically-apparent tumors close to 1:1000 of the general population. They are clinically significant beause of ... [more ▼]

Pituitary adenomas are one of the most frequent intracranial tumors with a prevalence of clinically-apparent tumors close to 1:1000 of the general population. They are clinically significant beause of hormone overproduction and/or tumor mass effects in addition to the need for neurosurgery medical therapies and radiotherapy. The majority of pituitary adenomas have a sporadic origin with recognized genetic mutations seldom being found; somatotropinomas are an exception, presenting frequent somatic GNAS mutations. In this and other phenotypes, tumorigenesis could possibly be explained by altered function of genes implicated in cell cycle regulation, growth factors or their receptors, cell-signaling pathways, specific hormonal factors or other molecules with still unclear mechanisms of action. Genetic changes, such as allelic loss or gene amplification, and epigenetic changes, usually by promoter methylation, have been implicated in abnormal gene expression, but alternative mechanisms may be present. Familial cases of pituitary adenomas represent 5% of all pituitary tumors. MEN1 mutations cause multiple endocrine neoplasia type 1 (MEN1), while the Carney complex (CNC) is charcaterized by mutations in the protein kinase A regulatory subunit-1alpha (PRKAR1A) gene or changes in a locus at 2p16. Recently, a MEN1-like conditions, MEN4, was found to be related to mutations in the CDKN1B gene. The clinical entity of familialt isolated pituitary adenomas (FIPA) is characterized by genetic defects in the aryl hydrocarbon receptor interacting protein (AIP) gene in about 15% of all kindreds and 50% of homogenous somatotropinoma families. Identification of familial cases of pituitary adenomas is important as these tumors may be more aggressive than their sporadic counterparts. [less ▲]

Detailed reference viewed: 26 (5 ULg)
See detailHyperplasia-adenoma sequence in pituitary tumorigenesis related to AIP mutation
Daly, Adrian ULg; Beckers, Albert ULg

in ENDO 2010 : The 92nd Annual Meeting (2010, June)

Detailed reference viewed: 10 (1 ULg)
See detailCharacterization of prolatinomas resistant to dopaminergic agonists
Vroonen, Laurent ULg; Daly, Adrian ULg; Beckers, Albert ULg

in ENDO 2010 : The 92nd Annual Meeting (2010, June)

Detailed reference viewed: 12 (3 ULg)
See detailFamilial Isolated Pituitary Adenomas
Beckers, Albert ULg

Scientific conference (2010, June)

Detailed reference viewed: 10 (2 ULg)
See detailAdénomes hypophysaires familiaux
Beckers, Albert ULg

Scientific conference (2010, May 28)

Detailed reference viewed: 11 (2 ULg)
Full Text
See detailLa pathologie hypothalamo-hypophysaire post-traumatique
VALDES SOCIN, Hernan Gonzalo ULg; Beckers, Albert ULg

Conference (2010, April 24)

Detailed reference viewed: 12 (3 ULg)
See detailProblèmes hypophysaires suite à une lésion cérébrale aigüe
Beckers, Albert ULg

Scientific conference (2010, April 23)

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailThe R304X mutation of the Aryl hydrocarbon receptor Interacting Protein gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect?
Occhi, G.; Jaffrain-Rea, M. L.; Trivellin, G. et al

in Journal of Endocrinological Investigation (2010), 33

Background: Mutations in the Aryl hydrocarbon receptor Interacting Protein (AIP) gene have been described in about 15% of kindreds with Familial Isolated Pituitary Adenomas (FIPA) and in a minority of ... [more ▼]

Background: Mutations in the Aryl hydrocarbon receptor Interacting Protein (AIP) gene have been described in about 15% of kindreds with Familial Isolated Pituitary Adenomas (FIPA) and in a minority of early onset sporadic pituitary adenomas (PA). Among the AIP mutations reported so far, the R304X (AIPR304X) represents, together with the "Finnish mutation" Q14X, the most common one. Methods: Three AIPR304X Italian families, including a newly reported kindred, have been genotyped for 12 genetic markers surrounding the AIP gene in order to look for a potential founder effect in Italy. Disease penetrance and genotype-phenotype correlations were also addressed. Results: Analysis of chromosome 11' genetic markers revealed a common haplotype in two AIPR304X kindreds originating from central Italy. Overall, seventeen mutations carriers were identified, including 7 patients and 10 unaffected subjects, respectively, arguing in this case for a disease penetrance of 41%. Mean age at diagnosis was 19.1+/-6.7 years-old, with females tending to be older than males. Though most PA were somatotropinomas (6/7), a great variability in disease severity was observed, even between subjects sharing the same at-risk haplotype. Conclusion: These data provide strong evidence for a new founder effect of the AIPR304X mutation in central Italy and the observed variations in disease severity point out the role of additional genetic or environmental factors in such kindreds. [less ▲]

Detailed reference viewed: 48 (4 ULg)
See detailRecent Management of acromegaly
Beckers, Albert ULg

Scientific conference (2010, March)

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailHigher prevalence of clinically relevant pituitary adenomas confirmed.
Beckers, Albert ULg

in Clinical Endocrinology (2010), 72(3), 290-291

Detailed reference viewed: 12 (7 ULg)